Latest News

Advances in DNA sequencing, tissue engineering, cellular reprogramming and gene editing could make it possible to accurately predict an individual's risk of disease or better target treatment at...

AVITA Medical (ASX:AVH),  a regenerative medicine company with a technology platform designed to address unmet medical needs in therapeutic skin restoration, has announced new preliminary data relating to its RECELL Autologous Cell Harvesting Device.

Melbourne-based Telix Pharmaceuticals (ASX:TLX) has announced the extension of its research collaboration with the Institute for Radiation Sciences (IRS), Osaka University and the Department of Nuclear Medicine and Tracer Kinetics at Osaka University Graduate School of Medicine.

Digital health company ResApp Health (ASX:RAP) has announced it has received $1.785 million from its R&D tax incentive claim for the financial year ending 30 June 2018.

Sydney-based cannabis company Creso Pharma (ASX:CPH) has agreed to be acquired by Canadian company PharmaCielo for $122 million.

Perth-based Proteomics International Laboratories (ASX:PIQ) says it has been invited to feature on the American Diabetes Association TV News Network during the ADA 79th Scientific Sessions conference in San Francisco.

The GCF grants provide up to $50,000 for Australian researchers and businesses to support the development of their products.

The current AusBiotech board member and former Bristol-Myers Squibb senior market access executive was appointed as the first industry nominated committee member in 2017.

The company has not disclosed any plans to launch ZYNTEGLO in Australia or anywhere in the southern hemisphere.

A new report released at the annual international convention of BIO has revealed the staggering scale and contribution of the US-based bioscience sector.

Work is underway planning the September edition of the Australasian Biotechnology journal, and AusBiotech members are invited to submit an article abstract for consideration.

Australian company Microba has launched an R&D program at BIO in Philadelphia focused on the prevalent and incurable Inflammatory Bowel Disease.